From the Horae Gene Therapy Center, Department of Pediatrics, University of Massachusetts Medical School (UMMS) (C.M., G.G., M.B., T.R.F.), and the Department of Neurology, UMMS and UMass Memorial Medical Center (D.M.M.-Y., M.A.O., C.L.D., N.S.W., R.H.B.), Worcester, and the Healey Center for ALS, Department of Neurology (J.D.B., L.M.P., D.G., S.D.L., M.P.F., M.E.C.), and the C.S. Kubik Laboratory for Neuropathology (D.H.O., M.P.F.), Massachusetts General Hospital and Harvard Medical School, Boston.
N Engl J Med. 2020 Jul 9;383(2):151-158. doi: 10.1056/NEJMoa2005056.
Two patients with familial amyotrophic lateral sclerosis (ALS) and mutations in the gene encoding superoxide dismutase 1 () were treated with a single intrathecal infusion of adeno-associated virus encoding a microRNA targeting SOD1. In Patient 1, SOD1 levels in spinal cord tissue as analyzed on autopsy were lower than corresponding levels in untreated patients with SOD1-mediated ALS and in healthy controls. Levels of SOD1 in cerebrospinal fluid were transiently and only slightly lower in Patient 1 but were not affected in Patient 2. In Patient 1, meningoradiculitis developed after the infusion; Patient 2 was pretreated with immunosuppressive drugs and did not have this complication. Patient 1 had transient improvement in the strength of his right leg, a measure that had been relatively stable throughout his disease course, but there was no change in his vital capacity. Patient 2 had stable scores on a composite measure of ALS function and a stable vital capacity during a 12-month period. This study showed that intrathecal microRNA can be used as a potential treatment for SOD1-mediated ALS.
两位家族性肌萎缩侧索硬化症(ALS)患者携带编码超氧化物歧化酶 1(SOD1)的基因突变,接受了单次鞘内注射编码靶向 SOD1 的 microRNA 的腺相关病毒。在 1 号患者中,尸检时分析脊髓组织中的 SOD1 水平低于未经治疗的 SOD1 介导的 ALS 患者和健康对照者相应水平。1 号患者的脑脊液 SOD1 水平短暂且仅略有降低,但 2 号患者不受影响。1 号患者在输注后发生脑膜炎神经根炎;2 号患者接受了免疫抑制药物预处理,没有这种并发症。1 号患者右腿力量有短暂改善,这一措施在他的整个病程中一直相对稳定,但肺活量没有变化。2 号患者在 12 个月期间,综合 ALS 功能评分和稳定的肺活量保持稳定。这项研究表明,鞘内 microRNA 可作为治疗 SOD1 介导的 ALS 的一种潜在方法。